等待開盤 09-17 09:30:00 美东时间
-0.470
-1.09%
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Fin...
09-03 20:07
LB Pharmaceuticals has appointed Joseph Miller as its Chief Financial Officer. With over 20 years of experience in biopharmaceutical finance, Miller brings expertise in financial strategy, operations, and organizational growth. His appointment coincides with the company's pivotal NOVA-2 clinical trial for LB-102, a potential schizophrenia treatment. Miller's leadership at Aurinia Pharmaceuticals and Avalo Therapeutics, where he successfully scale...
09-03 12:00
今日重点评级关注:Truist Securities:维持CoreWeave"买入"评级,目标价从155美元升至165美元;百德:维持亚德诺"跑赢大市"评级,目标价从450美元升至675美元
08-25 11:47
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird cut the price target for Chipotle Mexican Grill Inc (NYSE:CMG) from $44 to $40. Baird analyst Chris O’Cu...
08-24 21:30
HC Wainwright & Co. analyst Raghuram Selvaraju maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $45 to $60.
08-24 18:06
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从49美元升至56美元;韦德布什:维持Zura Bio"跑赢大市"评级,目标价从15美元升至22美元
08-13 11:44
BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.
08-12 20:05
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per share from the same period last year.
08-11 20:05
LB Pharmaceuticals announced the accelerated timeline for top-line data from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia, expected in the first half of 2027. The company also plans to expand LB-102's pipeline into new neuropsychiatric indications, supported by clinical and real-world experience from amisulpride. As of June 30, 2026, the company had $327.8 million in cash, cash equivalents, and marketable securities, plus $150 mill...
08-11 12:00
今日重点评级关注:HC Wainwright & Co.:维持Enlivex"买入"评级,目标价从20美元升至80美元;Canaccord Genuity:维持Pharming Group NV Sponsored ADR"买入"评级,目标价从37美元升至38美元
08-04 11:45